BR112013014360A2 - método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção - Google Patents

método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção

Info

Publication number
BR112013014360A2
BR112013014360A2 BR112013014360A BR112013014360A BR112013014360A2 BR 112013014360 A2 BR112013014360 A2 BR 112013014360A2 BR 112013014360 A BR112013014360 A BR 112013014360A BR 112013014360 A BR112013014360 A BR 112013014360A BR 112013014360 A2 BR112013014360 A2 BR 112013014360A2
Authority
BR
Brazil
Prior art keywords
marker
sample
target
detecting
proximally
Prior art date
Application number
BR112013014360A
Other languages
English (en)
Other versions
BR112013014360B8 (pt
BR112013014360B1 (pt
Inventor
Adrian E Murillo
Eric J May
Jerome W Kosmeder
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Publication of BR112013014360A2 publication Critical patent/BR112013014360A2/pt
Publication of BR112013014360B1 publication Critical patent/BR112013014360B1/pt
Publication of BR112013014360B8 publication Critical patent/BR112013014360B8/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção esta descrição refere-se a composições que realçam a deposição de porções químicas detectáveis em amostras de tecido, sendo que os métodos utilizam essas composições e kits que incluem essas composições. as composições incluem um realçador de deposição que tem uma fórmula e/ou em que r^ 1^, r^ 2^, r^ 3^ e r^ 4^ são independetemente selecionados dentre uma porção química que contém heteroátomo, alifática, arila, halogênio e hidrogênio; r^ 1^ e/ou r^ 3^ podem ser ligados a r^ 2^ para formar um sistema de anel aromático fundido; r^ 5^ é selecionado dentre uma porção química que contém heteroátomo; a é selecionado dentre um átomo de carbono, um heteroátomo, exceto enxofre, e qualquer combinação dos mesmos; n é 1 a 5, uma enzima, uma porção química de ligação específica e uma porção química detectável.
BR112013014360A 2010-12-30 2011-12-28 método para detectar um alvo em uma amostra e kit BR112013014360B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061460349P 2010-12-30 2010-12-30
US61/460,349 2010-12-30
PCT/US2011/067481 WO2012092322A1 (en) 2010-12-30 2011-12-28 Enhanced deposition of chromogens utilizing pyrimidine analogs

Publications (3)

Publication Number Publication Date
BR112013014360A2 true BR112013014360A2 (pt) 2016-10-04
BR112013014360B1 BR112013014360B1 (pt) 2020-10-13
BR112013014360B8 BR112013014360B8 (pt) 2020-12-15

Family

ID=45554795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014360A BR112013014360B8 (pt) 2010-12-30 2011-12-28 método para detectar um alvo em uma amostra e kit

Country Status (14)

Country Link
US (2) US8871442B2 (pt)
EP (2) EP3088534B1 (pt)
JP (2) JP5815046B2 (pt)
KR (1) KR101554795B1 (pt)
CN (1) CN103282516B (pt)
AU (2) AU2011352251B2 (pt)
BR (1) BR112013014360B8 (pt)
CA (2) CA2817374C (pt)
DK (2) DK2659000T3 (pt)
ES (2) ES2593464T3 (pt)
HK (1) HK1185634A1 (pt)
IL (1) IL226479A (pt)
SG (2) SG190892A1 (pt)
WO (1) WO2012092322A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014360B8 (pt) * 2010-12-30 2020-12-15 Ventana Med Syst Inc método para detectar um alvo em uma amostra e kit
WO2013110549A1 (en) 2012-01-23 2013-08-01 Ventana Medical Systems, Inc. Polymer stabilization of chromogen solutions
AU2013240090B2 (en) 2012-03-27 2017-01-05 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US9651555B2 (en) 2012-09-24 2017-05-16 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
CN105164272A (zh) * 2013-02-28 2015-12-16 株式会社日冷生物科学 使用标记酶的染色用含dab底物试剂盒
EP3764084A1 (en) * 2013-03-12 2021-01-13 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
WO2015028382A1 (en) 2013-08-28 2015-03-05 Ventana Medical Systems, Inc. Immunohistochemical assay for detection of cd3 and cd16
EP3492919A3 (en) * 2014-02-24 2019-07-10 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
WO2017040349A1 (en) 2015-08-28 2017-03-09 Ventana Medical Systems, Inc. Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens
US10718694B2 (en) * 2016-04-18 2020-07-21 Diagnostic Biosystems Counterstains for a biological sample
JP7021126B2 (ja) * 2016-06-28 2022-02-16 ヴェンタナ メディカル システムズ, インク. マルチ色素キノンメチド及びチラミドコンジュゲートによる発色性ihc及びish染色のための新規の色
CN109641922A (zh) 2016-06-28 2019-04-16 文塔纳医疗系统公司 点击化学用于ihc和ish测定中的信号扩增的应用
EP3646006A1 (en) 2017-06-28 2020-05-06 Ventana Medical Systems, Inc. System level calibration
JP7455816B2 (ja) 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ, インク. クマリン系架橋試薬
JP2020071152A (ja) * 2018-10-31 2020-05-07 ソニー株式会社 免疫染色方法、免疫染色システム、および免疫染色キット
CA3190731A1 (en) 2020-08-28 2022-03-03 Mark Lefever Conjugates including a detectable moiety
JP2023542343A (ja) 2020-09-22 2023-10-06 ヴェンタナ メディカル システムズ, インク. エピレグリンおよびアンフィレグリンを用いた上皮増殖因子受容体指向性療法に対する応答の予測
JP2024504944A (ja) 2021-01-15 2024-02-02 ヴェンタナ メディカル システムズ, インク. 保存安定なケージドハプテン
EP4281779A1 (en) 2021-01-25 2023-11-29 Ventana Medical Systems, Inc. Stained biological specimens including one or more biomarkers labeled with one or more detectable moieties
JP2024516380A (ja) 2021-04-18 2024-04-15 ヴェンタナ メディカル システムズ, インク. 形態学的マーカー染色
WO2024137817A1 (en) 2022-12-23 2024-06-27 Ventana Medical Systems, Inc. Materials and methods for evaluation of antigen presentation machinery components and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564604A (en) 1925-06-12 1925-12-08 Chas S Hodges Water wheel
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4318984A (en) * 1979-11-13 1982-03-09 Miles Laboratories, Inc. Stabilized composition, test device, and method for detecting the presence of a sugar in a test sample
GB8713951D0 (en) 1987-06-15 1987-07-22 Dewar M H Enhanced chemiluminescent reaction
WO1990003370A1 (en) * 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
US5225325A (en) 1990-03-02 1993-07-06 Ventana Medical Systems, Inc. Immunohistochemical staining method and reagents therefor
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
GB9306888D0 (en) * 1993-04-01 1993-05-26 Kricka Larry J Chemiluminescent enhancers
JPH07308200A (ja) 1994-05-16 1995-11-28 Konica Corp ペルオキシダーゼ様物質の活性または酸化性物質の検出及び測定のための組成物並びに測定方法
KR0164072B1 (ko) 1995-11-13 1999-02-01 김주용 반도체 소자의 얕은 접합 형성방법
AU4980097A (en) * 1996-10-21 1998-05-15 University Of Iowa Research Foundation, The Efficient synthesis of nucleosides
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
ATE489613T1 (de) 1998-02-27 2010-12-15 Ventana Med Syst Inc Automatisierter molekularer pathologieapparat mit unabhängigen objektträgerwärmern
DE19834938C2 (de) 1998-07-29 2000-07-20 Coty Bv Verfahren zur kosmetischen Bräunungsbestimmung einer Selbstbräunungszusammensetzung und Test-Kit
US6372937B1 (en) 1998-11-09 2002-04-16 Mark Norman Bobrow Enhanced catalyzed reporter deposition
US6355443B1 (en) * 1999-03-17 2002-03-12 Mark Norman Bobrow 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020076732A1 (en) * 2000-12-15 2002-06-20 Kaplan David R. Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US6617125B2 (en) * 2001-06-29 2003-09-09 Perkinelmer Life Sciences, Inc. Compositions for enhanced catalyzed reporter deposition
EP1409240B1 (en) 2001-07-20 2012-05-09 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
EP1636586B1 (en) 2003-06-24 2009-07-22 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
BR112013014360B8 (pt) * 2010-12-30 2020-12-15 Ventana Med Syst Inc método para detectar um alvo em uma amostra e kit

Also Published As

Publication number Publication date
WO2012092322A1 (en) 2012-07-05
IL226479A0 (en) 2013-07-31
KR101554795B1 (ko) 2015-09-21
EP3088534B1 (en) 2018-08-01
AU2011352251A1 (en) 2013-05-23
AU2015207891A1 (en) 2015-08-20
CN103282516A (zh) 2013-09-04
JP5815046B2 (ja) 2015-11-17
BR112013014360B8 (pt) 2020-12-15
AU2011352251B2 (en) 2015-05-28
EP2659000A1 (en) 2013-11-06
BR112013014360B1 (pt) 2020-10-13
EP3088534A1 (en) 2016-11-02
AU2015207891B2 (en) 2016-12-15
JP2015212700A (ja) 2015-11-26
EP2659000B1 (en) 2016-08-10
CA3007179C (en) 2021-06-08
DK2659000T3 (en) 2016-08-29
CA2817374A1 (en) 2012-07-05
HK1185634A1 (en) 2014-02-21
CA2817374C (en) 2018-10-16
SG190892A1 (en) 2013-07-31
US8871442B2 (en) 2014-10-28
JP6130438B2 (ja) 2017-05-17
US9435795B2 (en) 2016-09-06
CA3007179A1 (en) 2012-07-05
JP2014502728A (ja) 2014-02-03
SG10201804238TA (en) 2018-06-28
IL226479A (en) 2017-01-31
ES2689593T3 (es) 2018-11-14
ES2593464T3 (es) 2016-12-09
KR20130138283A (ko) 2013-12-18
CN103282516B (zh) 2015-06-10
US20120171668A1 (en) 2012-07-05
US20150024405A1 (en) 2015-01-22
DK3088534T3 (en) 2018-10-15

Similar Documents

Publication Publication Date Title
BR112013014360A2 (pt) método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção
ES2552311T3 (es) Derivados heterocíclicos
BRPI0613429A2 (pt) inibidores de histona desacetilase
Tevatia et al. The taurine biosynthetic pathway of microalgae
BRPI0906104B8 (pt) derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
RU2017100015A (ru) Набор или устройство для обнаружения рака желчных путей и способ обнаружения
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
BR112012033091A2 (pt) método de cimentação, e, composição de cimento
BR112012008939A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt2
RS54083B1 (en) METASTINE DERIVATIVES AND THEIR USE
BR112012026147A2 (pt) espiroderivados azacíclicos como inibidores de hsl
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
BRPI0810661A2 (pt) [2,6] naftiridinas úteis como inibidoras de quinase proteica.
UA105296C2 (ru) Определение и подсчет микроорганизмов
CY1118170T1 (el) Νεα φωσφινικα οξεα και παραγωγα θειου αυτων και μεθοδοι για την παρασκευη τους
ECSP099351A (es) Compuestos heterociclicos y su uso como inhibidores de la
Zhu et al. A detective story in drug discovery: elucidation of a screening artifact reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase.
CY1116496T1 (el) Στεροειδη c-19 για θεραπευτικες χρησεις
WO2012027266A3 (en) Methods for dectecting embryonic stem cells, induced pluripotent stem cells, or cells undergoing reprogramming to produce induced pluripotent stem cells
ATE493110T1 (de) Kosmetische zusammensetzung zur stimulierung der synthese der proteine der basalmembran
ATE538216T1 (de) Nukleinsäureverstärkung mithilfe eines reversibel modifizierten oligonukleotids
BR112022010054A2 (pt) Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2597 DE 13/10/2020 QUANTO AO RELATORIO DESCRITIVO.